Opening the door to backroom biologics


Automated benchtop systems are beginning to integrate oligonucleotide synthesis and protein production. Given economic pressures to innovate in drug manufacture and the potential of platform production technologies to enable decentralization, a future in which the brand manufacturers’ monopoly on biologics could be broken is feasible. 

Content Information

Content Author: 
unknown
Content Source: 
Nature Biotechnology
Content Type: 
News